

October 2, 2024

Statement of Appreciation on Senator Van Hollen's Treatment Centers Act Legislation

The Sickle Cell Disease Partnership commends Senator Van Hollen for his introduction of <u>S. 5226/H.R. 9872</u>, *Sickle Cell Disease Treatment Centers Act of 2024*. This legislation would help to improve access to care and treatment for Americans with Sickle Cell Disease – the most common inherited blood disorder in the United States. Today, more than 100,000 Americans have Sickle Cell Disease, and millions of Americans have a family member, friend, neighbor, or colleague whose life has been touched by the disease.

This legislation would help to close care gaps and improve access to treatment. We appreciated the opportunity to provide feedback on a draft version of the legislation and are grateful that much of our feedback was incorporated. We look forward to continuing to work with Senator Van Hollen and other members, on a bipartisan basis, to improve and advance legislation that can help to reduce disparities, increase access, and improve health care quality and outcomes for Americans with Sickle Cell Disease.

About the Sickle Cell Disease Partnership

The Partnership is a public policy and advocacy alliance of more than a dozen healthcare and SCD organizations working together to advance federal policies to improve the lives of Americans with SCD.

For more information, please visit www.SickleCellPartnership.org. You may also email the advisors to the Partnership, Josh.Trent@LeavittPartners.com, Elizabeth.Hassett@LeavittPartners.com, and Clay.Alspach@LeavittPartners.com.

